Evidence map›Paper›PMID 30243041›Full record

ReviewCurrent opinion in structural biology2018

Predicting allostery and microbial drug resistance with molecular simulations.

George A Cortina, Peter M Kasson

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in structural biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

George A CortinaDepartments of Molecular Physiology and of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, United States.
Peter M KassonDepartments of Molecular Physiology and of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, United States; Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala 75146, Sweden. Electronic address: kasson@virginia.edu.
University of Virginia · USUppsala University · SE

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
Identifying Determinants of Carbapenem Resistance in Beta-lactamasesF31GM113543 · NIGMS · UNIVERSITY OF VIRGINIA · PI CORTINA, GEORGE · 2017 to 2018
$72k
NIGMS NIH HHS F31 GM113543NIGMS NIH HHS T32 GM007267
6 · The paper itself

Abstract

Beta-lactamase enzymes mediate the most common forms of gram-negative antibiotic resistance affecting clinical treatment. They also constitute an excellent model system for the difficult problem of understanding how allosteric mutations can augment catalytic activity of already-competent enzymes. Multiple allosteric mutations have been identified that alter catalytic activity or drug-resistance spectrum in class A beta lactamases, but predicting these in advance continues to be challenging. Here, we review computational techniques based on structure and/or molecular simulation to predict such mutations. Structure-based techniques have been particularly helpful in developing graph algorithms for analyzing critical residues in beta-lactamase function, while classical molecular simulation has recently shown the ability to prospectively predict allosteric mutations increasing beta-lactamase activity and drug resistance. These will ultimately achieve the greatest power when combined with simulation methods that model reactive chemistry to calculate activation free energies directly.

Indexed as

Drug Resistance, MicrobialModels, MolecularAllosteric RegulationAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCatalysisHumansMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureMutationStructure-Activity RelationshipAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamases

Identifiers

PMID30243041
PMCPMC6296865
OpenAlexW2890406195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.